Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 20 tags : Fda save search
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 0.56%
H: 0.3%
C: 0.19%
fda application license biosimilar
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
Published: 2021-12-20 (Crawled : 18:00) - biospace.com/
ITCI 4 d | $74.58 3.05% 2.96% 1.9M
|
Health Technology
|
| O: 12.0%
H: 11.72%
C: 3.4%
caplyta treatment fda fda approval approval cel depression therapy
Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors
Published: 2021-12-20 (Crawled : 15:30) - biospace.com/
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: -1.46%
H: 1.49%
C: -2.34%
sti-1386 fda clearance solid tumors application therapeutics fda clearance
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
Published: 2021-12-20 (Crawled : 15:00) - biospace.com/
CHRS | $2.19 5.8% 5.48% 1.5M
|
Health Technology
|
| O: 1.85%
H: 1.17%
C: 0.64%
fda fda approval approval
Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia
Published: 2021-12-20 (Crawled : 15:00) - biospace.com/
EDIT | News | $5.62 2.37% 2.31% 1.7M
|
Health Technology
|
| O: 4.96%
H: 6.56%
C: 4.21%
edit-301 new drug treatment fda clearance transfusion application drug fda clearance
EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
EW | $86.96 1.19% 0.0% 2.4M
|
Health Technology
|
| O: -1.38%
H: 0.43%
C: -0.34%
fda fda approval approval sap
Bioventus Receives US FDA Clearance for BoneScalpel® Access™
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
BVS 4 | $4.28 -4.46% -4.67% 140K
|
|
| O: -1.21%
H: 3.29%
C: -1.76%
bonescalpel fda clearance bone fda clearance
PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
PTE | $0.241 -0.82% -6.68% 0
|
Consumer Durables
|
| O: 2.56%
H: 8.75%
C: 8.7%
skinte clinical hold new drug fda application drug skin pons submission response
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors
Published: 2021-12-20 (Crawled : 14:00) - biospace.com/
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: 7.29%
H: 8.01%
C: 7.4%
new drug fda clearance solid tumors application car-t drug therapeutics fda clearance
Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)
Published: 2021-12-20 (Crawled : 13:00) - biospace.com/
ETON | $3.26 2.19% 2.15% 40K
|
Health Technology
|
| O: 3.27%
H: 1.22%
C: 0.24%
ANIP S | $65.5 0.03% 0.03% 95K
|
Health Technology
|
| O: -0.85%
H: 4.61%
C: 2.15%
carbaglu fda als
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.